de mortalidade. Disponível em: https://mortalidade.inca.gov.br. Acessado em: 15 de julho de 2015.
3. PARKIN D.M., BRAY F.I., DEVESA S.S. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001; 37(suppl 8):4-66.
4. RIES L., EISNER M., KOSARY C.L., et al. SEER Cancer Statistics Review, 1975-2001. Bethesda, MD: National Cancer Institute, 2004.
5. BERRY D.A., CRONIN K.A., PLEVRITIS S.K., et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353(17):1784-92.
6. ALLEMANI C., WEIR H.K., CARREIRA H., et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015; 385(9972):977-1010.
7. NEWMAN L.A. Epidemiology of locally advanced breast cancer. Semin Radiat Oncol. 2009; 19(4):195-203.
8. GIORDANO S.H. Update on locally advanced breast cancer. Oncologist. 2003; 8(6):521-30.
9. THULER L.C.S.; MENDONÇA G.A. Estadiamento inicial dos casos de câncer de mama e colo do útero em mulheres brasileiras. Rev Bras Ginecol Obstet. 2005; 27(11):656-60.
10. BELL D.W. Our changing view of the genomic landscape of cancer. J Pathol. 2010; 220(2):231-43.
11. PEROU C.M., SØRLIE T., EISEN M.B., et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52.
12. SØRLIE T., PEROU C.M., TIBSHIRANI R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19):10869-74.
13. MAMOUNAS E.P., TANG G., FISHER B., et al. Association between the 21- gene recurrence score assay and risk of locoregional recurrence in node- negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010; 28(10):1677-83.
14. CAREY L.A.; PEROU C.M.; LIVASY C.A.; DRESSLER L.G.; COWAN D.; CONWAY K.; et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295(21):2492-2502.
15. PETIT A.M., RAK J., HUNG M.C., et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo:
angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997; 151(6):1523-30.
16. GIATROMANOLAKI A., KOUKOURAKIS M.I., SIMOPOULOS C., et al. c- erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor- 1alpha dependent. Clin Cancer Res. 2004; 10(23):7972-7.
17. SLAMON D.J., LEYLAND-JONES B., SHAK S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-92.
18. KAUFMANN M., VON MINCKWITZ G., MAMOUNAS E.P., et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012; 19(5):1508-16.
19. ESSERMAN L.J., DEMICHELE A. Accelerated approval for pertuzumab in the neoadjuvant setting: winds of change? Clin Cancer Res. 2014; 20(14):3532- 6.
20. CAREY L.A., WINER E.P. Defining success in neoadjuvant breast cancer trials. Lancet. 2014; 384(9938):115-6.
21. MIEOG J.S., VAN DE VELDE C.J. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007; (2):CD005002. 22. VON MINCKWITZ G., UNTCH M., BLOHMER J.U., et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012; 30(15):1796-1804.
23. CORTAZAR P., ZHANG L., UNTCH K., et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384(9938):164-72.
24. CAREY L.A., WINER E.P. Defining success in neoadjuvant breast cancer trials. Lancet. 2014; 384(9938):115-6.
25. FISHER B., BRYANT J., WOLMARK N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998; 16(8):2672-85.
26. WOLMARK N., WANG J., MAMOUNAS E., et al. Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001; (30):96-102.
27. BEAR H.D., ANDERSON S., BROWN A., et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003; 21(22):4165-74.
28. VON MINCKWITZ G., REZAI M., LOIBL S., et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol. 2010; 28(12):2015-23. 29. BEAR H.D., TANG G., RASTOGI P., et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012; 366(4):310- 20.
30. HUOBER J., VON MINCKWITZ G., DENKERT C., et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat. 2010; 124(1):133-40.
31. RASTOGI P., ANDERSON S.J., BEAR H.D., et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008; 26(5):778-85.
32. SINGER C.F., KLINGLMÜLLER F., STRATMANN R., et al. Response prediction to neoadjuvant chemotherapy: comparison between pre-therapeutic gene expression profiles and in vitro chemosensitivity assay. PLoS One. 2013; 8(6):e66573.
33. LIN N.U., VANDERPLAS A., HUGHES M.E., et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012; 118(22):5463-72.
34. VON MINCKWITZ G., SCHNEEWEISS A., LOIBL S., et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014; 15(7):747-56.
35. SIKOV W.M., BERRY D.A., PEROU C.M., et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic
complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015; 33(1):13-21.
36. PETRELLI F., BORGONOVO K., CABIDDU M., et al. Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials. Anticancer Drugs. 2011; 22(2):128-35.
37. UNTCH M., FASCHING P.A., KONECNY G.E., et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011; 29(25):3351-7.
38. UNTCH M., LOIBL S., BISCHOFF J., et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012; 13(2):135-44.
39. BASELGA J., BRADBURY I., EIDTMANN H., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012; 379(9816):633-40.
40. GUARNERI V., FRASSOLDATI A., BOTTINI A., et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol. 2012; 30(16):1989-95.
41. PICCART-GEBHART M.J., HOLMES A.P., BASELGA J., et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing
one year of anti-HER2 therapy with lapatinib alone (L), trastuzumabe alone (T), their sequence (T-L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC) [abstract]. J Clin Oncol. 2014; 32:LBA4. 42. DEMICHELE A., YEE D., BERRY D.A., et al. The neoadjuvant model is still the future for drug development in breast cancer? Clin Cancer Res. 2015; 21(13):2911-5.
43. GIANNI L., PIENKOWSKI T., IM Y.H., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13(1):25-32.
44. SCHNEEWEISS A., CHIA S., HICKISH T., et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013; 24(9):2278-84.
45. ESSERMAN L.J., DEMICHELE A., et al. Accelerated approval for pertuzumab in the neoadjuvant setting: winds of change? Clin Cancer Res. 2014; 20(14):3632-6.
46. COLLEONI M., VIALE G., ZAHRIEH D., et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res. 2004; 10(19):6622-8.
47. RING A.E, SMITH I.E., ASHLEY S., et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 2004; 91(12):2012-7.
48. GOLDHIRSCH A., WINER E.P., COATES A.S., et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24(9):2206-23.
49. BERRY D.A., CIRRINCIONE C., HENDERSON I.C., et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive cancer. JAMA. 2006; 295(14):1658-67.
50. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378(9793):771-84.
51. PREECE P.E., WOOD R.A., MACKIE C.R., et al. Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. Br Med J (Clin Res Ed). 1982; 284(6319):869-70.
52. BERGMAN L., VAN DONGEN J.A., VAN OOIJEN B., et al. Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease? Breast Cancer Res Treat. 1995; 34(1):77-83.
53. CHAKRABARTI J., KENNY F.S., SYED B.M., et al. A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable
primary breast cancer-final results at 20-year follow-up. Crit Rev Oncol Hematol. 2011; 78(3):260-4.
54. HIND D., WYLD L., BEVERLEY C.B., REED M.W. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev. 2006; (1):CD004272.
55. SEO J.H., KIM Y.H., KIM J.S. Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor- positive breast cancer. Cancer Chemother Pharmacol. 2009; 63(2):261-6.
56. SEMIGLAZOV V.F., SEMIGLAZOV V.V., DASHYAN G.A., et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007; 110(2):244-54.
57. ALBA E., CALVO L., ALBANELL J., et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol. 2012; 23(12):3069-74.
58. YERUSHALMI R., WOODS R., RAVDIN P.M., et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010; 11(2):174-83.
59. HU Z., FAN C., OH D.S., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006; 7:96.
60. PEROU C.M., JEFFREY S.S., VAN DE RIJN M., et al. Distinctive gene expression patterns in humam mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A. 1999; 96(16):9212-7.
61. DOWSETT M., NIELSEN T.O., A'HERN R., et al. Assessement of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. Breast. 2008; 17(4):323-34.
62. STUART-HARRIS R., CALDAS C., PINDER S.E., PHAROAH P. Proliferation markers and survival in early breast cancer: a sistematic review and meta- analysis of 85 studies in 32,825 patients. Breast. 2008; 17(4):323-34.
63. DE AZAMBUJA E., CARDOSO F., DE CASTRO G. JR, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007; 96(10):1504-13.
64. POLLEY M.Y., LEUNG S.C., MCSHANE L.M., et al. An international Ki67 reproducibility study. J Natl Cancer Inst. 2013; 105(24):1897-906.
65. HARRIS L., FRITSCHE H., MENNEL R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25(33):5287-312.
66. BONNEFOI H., DIEBOLD-BERGER S., THERASSE P., et al. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann Oncol. 2003; 14(3):406-13.
67. PENAULT-LLORCA F., ANDRÉ F., SAGAN C., et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009; 27(17):2809-15.
68. MOTTOLESE M., BENEVOLO M., DEL MONTE G., et al. Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline- based chemotherapy. J Cancer Res Clin Oncol. 2000; 126(12):722-9.
69. VIALE G., REGAN M.M., MASTROPASQUA M.G., et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst. 2008; 100(3):207- 12.
70. MICHALIDES R., VAN TINTEREN H., BALKENENDE A., et al. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer. 2002; 86(3):402-8.
71. VIALE G., GIOBBIE-HURDER A., REGAN M.M., et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008; 26(34):5569-75.
72. MACGROGAN G., MAURIAC L., DURAND M., et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer. 1996; 74(9):1458-65.
73. BOTTINI A., BERRUTI A., BRIZZI M.P., et al. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial. Endocr Relat Cancer. 2005; 12(2):383-92.
74. GENERALI D., BUFFA F.M., BERRUTI A., et al. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol. 2009; 27(2):227-34.
75. VON MINCKWITZ G., SINN H.P., RAAB G., et al. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res. 2008; 10(2):R30.
76. LUPORSI E., ANDRÉ F., SPYRATOS F., et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat. 2012; 132(3):895-91.
77. CHEANG M.C.U., CHIA S.K., VODUC D., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009; 101(10):736-50.
78. TAMAKI K., ISHIDA T., TAMAKI N., et al. Analysis of clinically relevant values of Ki67 labeling index in Japanese breast cancer patients. Breast Cancer. 2014; 21(3):325-33.
79. SUETA A., YAMAMOTO Y., HAYASHI M., et al. Clinical signifcance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes?. Surgery. 2014; 155(5):927-35.
80. HORIMOTO Y., ARAKAWA A., TANABE M., et al. Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer. BMC Cancer. 2014; 14:550.
81. FASCHING P.A., HEUSINGER K., HAEBERLE L., et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 2011; 11:486.
82. BALMATIVOLA D., MARCHIÒ C., MAULE M., et al. Pathological non- response to chemotherapy in a neoadjuvant setting of breast cancer: an inter- institutional study. Breast Cancer Res Treat. 2014; 148(3):511-23.
83. JONES R.L., SALTER J., A'HERN R., et al. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2010; 119(2):315-23.
84. TAN Q.X., QIN Q.H., YANG W.P., et al. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. Int J Clin Exp Pathol. 2014; 7(10):6862-70.
85. YOSHIOKA T., HOSODA M., YAMAMOTO M., et al. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Breast Cancer. 2015; 22(2):185-91.
86. DENKERT C., LOIBL S., MÜLLER B.M., et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol. 2013; 24(11):2786-93.
87. ASSERSOHN L., SALTER J., POWLES T.J., et al. Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat. 2003; 82(2):113-23.
88. JONES R.L., SALTER J., A'HERN R., et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009; 116(1):53-68.
89. SHERI A., SMITH I.E., JOHNSTON S.R., et al. Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. Ann Oncol. 2015; 26(1):75-80.
90. OHNO S., CHOW L.W., SATO N., et al. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluoruracil-epirubicin- cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2013; 142(1):69-80.
91. TANEI T., SHIMOMURA A., SHUMAZU K., et al. Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol. 2011; 37(2):155-61.
92. VON MINCKWITZ G., SCHMITT W.D., LOIBL S., et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res. 2013; 19(16):4521-31.